Freedom Biosciences is a startup based in the United Kingdom, most recent round Series A, 2 tracked investors.
Based in the United Kingdom, Freedom Biosciences is a startup founded in 2020. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation neuropsychiatric therapeutics, primarily focusing on ketamine-based and psychedelic combination therapies for mental health disorders such as depression and PTSD.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.